Stomach Cancer News and Research

RSS

Stomach cancer or gastric cancer affects around 7,000 people each year in the UK. Stomach cancer is difficult to detect in the early stages because the initial symptoms are also seen in less serious conditions such as persistent indigestion, heart burn, trapped wind, burping and stomach ache.

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

Scientists discover novel genes that are mutated in stomach cancer

An international team of scientists, led by researchers from the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore and National Cancer Centre of Singapore, has identified hundreds of novel genes that are mutated in stomach cancer, the second-most lethal cancer worldwide.

9 Apr 2012

H. pylori bacteria associated with elevated levels of HbA1c

A new study by researchers at NYU Langone Medical Center reveals that the presence of Helicobacter pylori (H. pylori) bacteria is associated with elevated levels of glycosylated hemoglobin (HbA1c), an important biomarker for blood glucose levels and diabetes.

15 Mar 2012

Cancer rates to fall among men but slightly rise among women by 2020: Report

The report says that due to the growing and ageing population the actual number of new cases will rise by almost 40 per cent on 2007 levels. But when that's converted to the number of cases per 100,000 people the results are surprising. Cancer rates in men will fall from 595 to 568 cases per 100,000 by 2020. That equates to about 85,000 cases. When it comes to women the rate is projected to rise from 394 to 408 cases per 100,000. That's equivalent to 65,000 new cases in 2020.

11 Mar 2012

DF/CHCC specialists recommend genetic counseling for children with Li-Fraumeni syndrome

Genetic specialists at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) are recommending that children being treated for sarcoma should be offered genetic counseling for Li-Fraumeni syndrome, a rare condition that greatly raises a person's risk of developing additional cancers.

9 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Biosensors capable of detecting lung cancer in exhaled breath

Tecnalia, through the Interreg project Medisen, is contributing to develop biosensors capable of detecting the presence of tumour markers of lung cancer in exhaled breath.

23 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

H. pylori bacterium produces urease to neutralize gastric acid

A research team led by scientists at the Chinese University of Hong Kong is releasing study results this week showing how a bacterium, Helicobacter pylori, that causes more than half of peptic ulcers worldwide and that has been implicated in stomach cancer has managed for eons to turn the acidic environment of the human gut into one in which it can thrive.

8 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

Advaxis completes ADXS-HER2 pre-IND meeting with FDA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, completed a pre-IND meeting with the FDA on November 22, 2011 to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.

23 Nov 2011

RWJF announces recipients of 2011 Community Health Leaders Award

The Robert Wood Johnson Foundation is proud to announce today the recipients of its 2011 Community Health Leaders Award, honoring 10 individuals who have overcome daunting odds to improve the health and quality of life for disadvantaged or underserved communities across the country.

9 Nov 2011

Study shows improvement in diagnosis time for bowel, oesophageal and pancreatic cancers

NEW research shows that bowel, oesophageal and pancreatic cancers have seen the greatest improvement in the time it takes from when a patient first visits their GP with symptoms to when they are diagnosed with the disease.

8 Nov 2011

SJH&MC the first in Southeast Michigan to offer Hyperthermic Intraperitoneal Chemotherapy

A unique treatment involving the use of hot chemotherapy is being offered at St. John Hospital and Medical Center. SJH&MC is the first hospital in Southeast Michigan and one of only approximately 20 centers nationwide to offer the treatment.

5 Nov 2011

SFDA approves China Medical Technologies' colorectal cancer assay

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that China's State Food and Drug Administration has approved the Company's real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog assay as a companion diagnostic test for the use of a targeted drug for the treatment of colorectal cancer patients.

13 Oct 2011

FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.

12 Oct 2011

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

Leica Microsystems, CMED partner to co-develop and market automated FISH kits

China Medical Technologies, Inc. (CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, and Leica Biosystems, a division of Leica Microsystems, a world leader in microscopes and scientific instruments, today announced that they have established a sales, research and development collaboration to co-develop and market automated FISH kits to be used on the Leica BOND system.

8 Aug 2011

Three-drug regimen more effective for treating H. pylori infection

Helicobacter pylori, the bacterium known to cause peptic ulcers, is also the primary cause of gastric cancer, which is a leading cancer killer globally.

20 Jul 2011